_256_384.jpg)
In FY21, the company reported a net profit of Rs 419 crores compared to Rs 101 crores in FY 20 and consolidated total income at Rs 6092 crores, up 19% Y-o-Y
It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)
Through the Sehat Sathi App business can access unsecured business loans at low interest
Substantial reduction in losses
The company is eligible for 12 months exclusivity from launch
Board declares interim dividend of Rs 2 per equity share
Ibuprofen and Famotidine Tablets is an AB-rated generic therapeutic equivalent version of Horizon Medicines LLC’s Duexis Tablets, 800 mg/26.6 mg
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
The company has been consistently reducing debt
Ibuprofen and Famotidine tablets approved by FDA
Subscribe To Our Newsletter & Stay Updated
